Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study.

Peter A Merkel, Shunsuke Furuta, Alojzija Hocevar, Phillip Seo, Curry Koening, Federico Alberici, Yoshiyuki Abe, Peter C Grayson, Aladdin J Mohammad, Gizem Ayan, Ertugrul Cagri Bolek, Omer Karadag, Roberto Padoan, Giacomo Emmi, Lorenzo Dagna, David Jayne, Carol A Langford, Andrea Hinojosa-Azaola, Fatma Alibaz-Oner, Sara Monti, Haner Direskeneli, Eduardo Martín-Nares, Seza Ozen, Kenneth J Warrington, Paul A Monach, Carol A McAlear, Nader A Khalidi, David Cuthbertson, Christian Pagnoux, Luca Moroni

Journal: Arthritis & rheumatology (Hoboken, N.J.) 2024;76(7):1120-1129

PMID: 38343337

Abstract

OBJECTIVE

We describe the demographics, clinical features, disease course, and survival of polyarteritis nodosa (PAN) through an international collaboration (GLOBAL-PAN).

METHODS

Patients with PAN were recruited between 1990 and 2020 from observational cohorts of nine countries across Europe, Japan, and North America. Eligibility was retrospectively defined using the European Medicines Agency classification algorithm. Patients with PAN related to hepatitis B virus (n = 12) and two monogenic diseases mimicking PAN, deficiency of adenosine deaminase 2 enzyme (n = 16) or familial Mediterranean fever (n = 11), were excluded. Data regarding organ involvement, relapse, disease-related damage, and survival were analyzed.

RESULTS

Three hundred fifty-eight patients (female:male ratio 174:184), including those with systemic PAN (sPAN, n = 282) and cutaneous PAN (n = 76), were included. Twenty-five were pediatric onset. Mean ± SD age at diagnosis was 44.3 ± 18.1 years. Constitutional symptoms (71.5%), cutaneous involvement (70.5%), musculoskeletal findings (69.1%), and neurologic features (48.0%) were common manifestations. Among patients with sPAN, gastrointestinal involvement and proteinuria over 400 mg/day were reported in 52.2% and 11.2%, respectively. During a median (interquartile range) 59.6 (99.5) months of follow-up, relapse occurred in 48.5% of patients. One, 5- and 10-year survival rates for sPAN were 97.1%, 94.0%, and 89.0%, respectively. Predictors of death for sPAN included age ≥65 years at diagnosis, serum creatinine at diagnosis >140 μmol/L, gastrointestinal manifestations, and central nervous system (CNS) involvement.

CONCLUSION

The spectrum of PAN remains a complex, multifaceted disease. Relapse is common. Age ≥65 years and serum creatinine >140 μmol/L at diagnosis, as well as gastrointestinal and CNS involvement, are independent predictors of death in sPAN.

© 2024 American College of Rheumatology.

Address: Hacettepe University, Ankara, Turkey.; Skåne University Hospital, Lund, Sweden, and University of Cambridge, Cambridge, UK.; National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.; Mount Sinai Hospital, Toronto, Ontario, Canada.; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Università di Pavia, Pavia, Italy.; Juntendo University School of Medicine, Tokyo, Japan.; University of Brescia and Spedali Civili Hospital, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy.; Marmara University School of Medicine Hospital, Istanbul, Turkey.; University of South Florida, Tampa, Florida.; IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.; McMaster University, Hamilton, Ontario, Canada.; University of Texas Health Austin.; Cleveland Clinic, Cleveland, Ohio.; University of Pennsylvania, Philadelphia.; Brigham and Women's Hospital, Boston, Massachusetts.; University of Padua, Padua, Italy.; Johns Hopkins University, Baltimore, Maryland.; Mayo Clinic, Rochester, Minnesota.; University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia.; Chiba University Hospital, Chiba, Japan.; University of Florence, Florence, Italy.; University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.